CLINICAL_TRIALS
trial_result
· 2024-07-17
Clinical Trial Update: SAbR For Oligo-Progressive Renal Cell Cancer. [Phase 2]
Summary
A Phase 2 clinical trial evaluating stereotactic ablative radiotherapy for oligoprogressive renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Texas Southwestern Medical Center | Conditions: Oligoprogressive Renal Cell Carcinoma | Phase 2 | Status: COMPLETED